Student or educator? Sign up with your school email and get 6 months of Pro free.
Cited by 265

The DOI matches its Crossref record; 94 of the 94 references it cites were found in a registry or an index.

Three subtypes of lung cancer fibroblasts define distinct therapeutic paradigms

Open access
Hu, Haichuan, Piotrowska, Zofia, Hare, Patricia J., Chen, Huidong, Mulvey, Hillary E., Mayfield, Aislinn, Noeen, Sundus, Kattermann, Krystina, Greenberg, Max, Williams, August, Riley, Amanda K., Wilson, Jarad J., Mao, Ying-Qing, Huang, Ruo-Pan, Banwait, Mandeep K., Ho, Jeffrey, Crowther, Giovanna S., Hariri, Lida P., Heist, Rebecca S., Kodack, David P., Pinello, Luca, Shaw, Alice T., Mino-Kenudson, Mari, Hata, Aaron N., Sequist, Lecia V., Benes, Cyril H., Niederst, Matthew J., Engelman, Jeffrey A.·2021·Cancer Cell

Abstract

Cancer-associated fibroblasts (CAFs) are highly heterogeneous. With the lack of a comprehensive understanding of CAFs' functional distinctions, it remains unclear how cancer treatments could be personalized based on CAFs in a patient's tumor. We have established a living biobank of CAFs derived from biopsies of patients' non-small lung cancer (NSCLC) that encompasses a broad molecular spectrum of CAFs in clinical NSCLC. By functionally interrogating CAF heterogeneity using the same therapeutics received by patients, we identify three functional subtypes: (1) robustly protective of cancers and highly expressing HGF and FGF7; (2) moderately protective of cancers and highly expressing FGF7; and (3) those providing minimal protection. These functional differences among CAFs are governed by their intrinsic TGF-β signaling, which suppresses HGF and FGF7 expression. This CAF functional classification correlates with patients' clinical response to targeted therapies and also associates with the tumor immune microenvironment, therefore providing an avenue to guide personalized treatment.

Overview

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1016/j.ccell.2021.09.003

Cites

94 of 94 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 94 references

Cited by

See all 265

Metadata

Authors
Hu, H., Piotrowska, Z., Hare, P. J., Chen, H., Mulvey, H. E., Mayfield, A., Noeen, S., Kattermann, K., Greenberg, M., Williams, A., Riley, A. K., Wilson, J. J., Mao, Y.-Q., Huang, R.-P., Banwait, M. K., Ho, J., Crowther, G. S., Hariri, L. P., Heist, R. S., Kodack, D. P., Pinello, L., Shaw, A. T., Mino-Kenudson, M., Hata, A. N., Sequist, L. V., Benes, C. H., Niederst, M. J., & Engelman, J. A.
Venue
Cancer Cell
Publisher
Elsevier BV
Published
2021-11
Volume
39
Issue
11
Pages
1531-1547.e10
ISSN
1535-6108 (ISSN-L)
OpenAlex
W3204600913
Cited by
265
References
94
FWCI
11.20
Type
journal article
Language
en
Open access
hybrid

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Three subtypes of lung cancer fibroblasts define distinct therapeutic paradigms. https://app.cochat.ai/papers/10.1016/j.ccell.2021.09.003
The paper
Hu, H., Piotrowska, Z., Hare, P. J., Chen, H., Mulvey, H. E., Mayfield, A., Noeen, S., Kattermann, K., Greenberg, M., Williams, A., Riley, A. K., Wilson, J. J., Mao, Y.-Q., Huang, R.-P., Banwait, M. K., Ho, J., Crowther, G. S., Hariri, L. P., Heist, R. S., . . . Engelman, J. A. (2021). Three subtypes of lung cancer fibroblasts define distinct therapeutic paradigms. Cancer Cell. https://doi.org/10.1016/j.ccell.2021.09.003

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.